VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations
Xiuning Le, MD, PhD, discusses the results of tepotinib in patients with advanced non-small cell lung cancer and a MET exon 14 skipping mutation.
Xiuning Le, MD, PhD, an assistant professor in the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the results of tepotinib (Tepmetko) in patients with advanced non-small cell lung cancer (NSCLC) and a MET exon 14 skipping mutation.
The phase 2 VISION trial (NCT02864992) was massively positive, says Le. In the 99 patients the investigators could report on, there was about 46% objective response rate. To get a real response, she says the tumor has to shrink by at least 30%. In the 99 patients, there was 90% tumor shrinkage.
Le says the hypothesis for the study was correct due to these findings. The small molecule inhibitor tepotinib works on the tumor and induces tumor shrinkage. There were some patients with more tumor shrinkage than others on the trial, but overall the results were positive and showed that tepotinib works for this patient population.
There was a median progression-free survival of 8.6 months with this drug by independent review committee and 9.5 months by investigator assessment.
